Lakefront Biotherapeutics NV
LKFT · XNASCIK 1421876fmd_0WN9FZH79WFVK1MCEF5QAZ0F81Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 16 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 130 | 127 | 279 | 835 | 478 | 234 | 241 | 240 | 276 | 1,112 |
| Cost of revenue | – | – | – | – | – | 2 | 12 | – | 35 | 30 |
| Gross profit | – | – | – | – | – | 233 | 229 | – | 241 | 1,083 |
| Research and development | 140 | 219 | 316 | 420 | 524 | 321 | 270 | 241 | 335 | 459 |
| Selling, general and administrative | 24 | 27 | 39 | 97 | 185 | 132 | 139 | 134 | 134 | 153 |
| Operating income | (11) | (90) | (47) | 369 | (179) | (172) | (131) | (88) | (188) | 295 |
| Interest expense | 0 | 1 | 1 | 1 | 9 | 12 | 7 | 2 | 1 | 1 |
| Income before taxes | 54 | (116) | (31) | 149 | (310) | (119) | (71) | 6 | (3) | 301 |
| Income tax expense | 0 | 0 | 1 | (0) | 1 | 1 | 1 | 10 | (2) | (19) |
| Net income from continuing operations | 54 | (116) | (32) | 149 | (311) | (121) | (71) | (4) | (1) | 319 |
| Net income | 54 | (116) | (29) | 150 | (305) | (103) | (218) | 212 | 74 | 321 |
| Net income to common shareholders | 54 | (116) | (29) | 150 | (305) | (103) | (218) | 212 | 74 | 321 |